Ulo Review 2026: Most Effective Hair Loss Treatments?

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Millions of people globally experience some form of hair loss, which typically increases with age. Pattern baldness, also known as androgenic alopecia (AGA), is the leading type, affecting more than half of men over 50 and a significant portion…

Read More

Best Topical Finasteride: We Tried 7 Products

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Pattern hair loss (androgenic alopecia) is increasingly prevalent with age, affecting many adult men and women. Topical finasteride is one of the most proven treatments available. However, choosing the right provider can be challenging in today’s saturated market, which…

Read More

Nektar Reports Phase 2b Proof-of-Concept for Rezpegaldesleukin in Severe Alopecia Areata

Nektar Therapeutics has announced topline results from its Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin (REZPEG) in patients with severe-to-very-severe alopecia areata (AA). The data establish clinical proof of concept and support advancement into Phase 3 development, positioning rezpegaldesleukin as a potential non-JAK option for this autoimmune hair-loss condition. What is Rezpegaldesleukin? Rezpegaldesleukin is a first-in-class…

Read More

Absci Doses First Participants in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenic Alopecia

Absci has announced that the first volunteers have now been dosed in its Phase 1/2a HEADLINE trial evaluating ABS-201, a novel anti-prolactin receptor (PRLR) antibody designed with the company’s generative AI platform. What is Absci? Absci is a biotech company focused on using generative AI and synthetic biology to design next-generation biologics. Their pitch is…

Read More

Cosmo has Announced Phase III Topline Results for Clascoterone 5% Solution in the Treatment of Androgenic Alopecia

Cosmo Pharmaceuticals has announced impressive topline results from its two pivotal Phase 3 trials evaluating clascoterone 5% topical solution for male androgenic alopecia (AGA). These data mark what may be the first major therapeutic breakthrough for male-pattern hair loss in over 30 years. What is Clascoterone? Clascoterone is a topical androgen receptor inhibitor designed to…

Read More

Does TRT Cause Hair Loss?

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Testosterone replacement therapy (TRT) can be a breakthrough for men with low testosterone levels. It has been shown to boost vitality, sexual function, muscle mass, and energy levels once lost to hormonal decline. However, this life-changing intervention is often…

Read More

Topical Dutasteride Before and After: Ultimate Guide

Commissions we earn from partner links on this page do not affect our opinions or evaluations. In recent years, topical dutasteride has captured increasing attention among people seeking alternatives to standard oral therapies, often due to intolerance or limited results. This surge is fueled by social media testimonials and before-and-after photos that highlight dramatic transformations.…

Read More

Veradermics’ VDPHL01: Extended-Release Oral Minoxidil in Phase 3 Trials for Pattern Hair Loss

Veradermics, a clinical-stage dermatology company, announced on October 16 the completion of an oversubscribed $150 million Series C financing round. The funding will support the advancement of its lead investigational candidate, VDPHL01—an extended-release oral formulation of minoxidil being studied for androgenic alopecia in both men and women. The company describes it as the first oral…

Read More

Topical Finasteride Dose: The Complete Guide

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Continuing our new approach, here is our complete guide to topical finasteride dosing. Top 3 Recommended Topical Finasteride Brands #1 Ulo (Editor’s Choice) #2 Hims #3 Keeps In this article, we’ll discuss the available clinical literature and how varying…

Read More